Led · Seed · Dec 2025

Myriad Wind Energy Systems has created a crane-free wind energy platform that mounts multiple small rotors in a modular framework, removing the need for heavy lifting equipment and costly access roads. This design lowers capital costs, shortens installation downtime and makes small-scale wind viable where conventional turbines struggle. Founded in 2021 and based in Stirling, the company holds two granted patents and has secured several letters of intent from prospective customers. Management is led by CEO Adam Harris alongside CTO Paul Pirrie and COO Peter Taylor. A 50 kW prototype is planned for installation in 2026, after which Myriad intends to run commercial pilots and launch the product broadly. With fresh funding, the firm will expand its engineering and commercial teams and establish manufacturing and supply-chain partnerships. Myriad positions its technology as a year-round complement to solar power, particularly for rural businesses facing high winter energy costs.

Led · Equity · Jun 2024

OGI Bio develops bioreactors and automated systems that enhance the efficiency and precision of microbial growth, supporting product development in health and beauty, food manufacturing, feedstock and greener alternatives to petrochemicals. The company is based at the Pentland Science Park outside Edinburgh. It has secured follow-on funding of £650,000 which it will use to accelerate planned expansion in the UK, US and Europe. CEO Alex McVey said the company will launch additional modules to complement existing market offerings and an enhanced software package to give customers greater flexibility in process control. The software update will allow customers to view, measure and control their culturing processes remotely. Tricapital Angels has been a partner since March 2022 and led this latest round alongside Scottish Enterprise, Merleview, Apollo and Old College Capital.

Participated · Seed · Apr 2024

Glen Clova Scientific (GCS) is developing a virus-like particle (VLP) technology platform that underpins a pipeline of biologic drug candidates for chronic inflammatory and autoimmune conditions. The company has three initial preclinical assets: GCS001 for senile pruritus, GCS002 for atopic dermatitis and GCS003 for eczema and asthma. GCS says its VLP platform can deliver enhanced performance and a simpler, more cost-effective manufacturing process compared with existing biologic drugs. The firm plans to advance preclinical development of these three assets and to exploit its platform in several non-pharmaceutical markets through partnerships. GCS was founded in 2022 as a spin-out from the University of Dundee. The recent financing provides capital to progress the pipeline and expand the proprietary technology platform.

Led · Equity · Feb 2024

Trademylux Limited, trading as sellmyartworks.com, is a Scottish art‑tech startup operating an online platform to power sales of pre‑owned art pieces through traditional auction houses or other routes. The platform offers a secure way to acquire and dispose of artwork, aiming to create liquidity and promote further art transactional activity. The company plans to use the new funding to launch the first in a series of luxury goods resale platforms. Trademylux anticipates first‑year sales of more than 300 artworks and expects a strong growth trajectory. The business was founded by Bob Corsie and raised external funding to support its launch and growth plans.

Participated · Equity · Jan 2024

Carcinotech’s core product, Carcino3D, enables manufacture of 3D‑printed micro‑tumors using cells derived from patient biopsies and blood samples to precisely simulate the tumor microenvironment and accelerate ethical drug screening. The company positions the technology to improve delivery of more effective, personalized cancer treatments and to support oncology drug development. Carcinotech works with global partners including leading pharma companies, surgeons, pathologists and clinicians as part of its commercialization strategy. In October the company announced a partnership with CELLINK to combine CELLINK’s bioprinting solutions with Carcinotech’s expertise in producing bioprinted living tumors. Carcinotech has built traction across the UK and Europe and plans US expansion later this year. The company has strengthened its board, which is chaired by Albert Nicholl, and launched a scientific advisory board last year with world‑renowned oncology leaders.